Screener / SEC EDGAR /CIK 0001727196 /10-K filed Mar 3, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Scholar Rock Holding Corp SRRK

Compare with peers Embed
New in the 10-K 36 paragraphs with nothing like them in the 10-K filed Feb 27, 2025 New in the 10-Q 66 paragraphs not in the 10-Q filed Aug 6, 2026 10-Q against the 10-K 155 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 27, 2025. A box jumps to the paragraph as filed, below.

36 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

36 paragraphs in Risk Factors of the 10-K filed Mar 3, 2026 with nothing like them in the 10-K filed Feb 27, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

Unfavorable pricing and reimbursement decisions in the EU could significantly delay or limit patient access to apitegromab, if approved, and materially reduce our anticipated revenues. Even if we obtain marketing authorization, the EU health technology assessment bodies and national payors may impose price reductions, require additional clinical or real world evidence, restrict reimbursement, or deny coverage altogether. Pricing and reimbursement negotiations in the EU are often lengthy, highly uncertain, and subject to country by country requirements, reference pricing, budget impact assessments, and mandatory discounts. As a result, the commercial viability of apitegromab in the EU may be materially impacted.

Read in the 10-K

In September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility. This facility was issued a Form 483 by the FDA in July 2025 and the inspection classification of this facility is OAI. The observations were related to the facility and were not specific to apitegromab. The CRL did not cite any other approvability concerns, including apitegromab’s efficacy and safety data or the third-party drug substance manufacturer. In November 2025, we completed an in-person Type A meeting with the FDA that included participation of representatives from the third-party fill-finish facility. Also in November 2025, the third-party fill-finish facility received a warning letter from the FDA and continues to work with the FDA to resolve the outstanding issues cited in the warning letter. We plan to resubmit the apitegromab BLA at such time after the facility resolves the cGMP deficiencies identified in the CRL, however, there can be no guarantee of the timing of the facility’s resolution of those deficiencies or that the FDA will approve apitegromab upon our resubmission of the BLA. The CRL has delayed our progress toward potential commercialization of apitegromab and we may be subject to additional risks such as a loss of our competitive advantage, increased litigation and other regulatory issues.

The CRL could also adversely affect the ongoing regulatory review of the apitegromab MAA by the EMA. As part of its review, the EMA has a mutual recognition agreement with the FDA, and we believe satisfactory resolution of the OAI classification will be necessary for MAA approval. The EMA may also require additional assurance regarding the

suitability of manufacturing sites prior to approval which could result in a delay in review timelines. GMP non-compliance at the third-party fill-finish facility could, in the most adverse scenario, even result in a negative CHMP opinion and refusal of the MAA by the European Commission.

Read in the 10-K

inability to obtain, applicable regulatory approvals would delay or prevent commercialization of apitegromab and could materially adversely impact our business and prospects.

Read in the 10-K

Patients in ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies, and OPAL, our Phase 2 clinical trial of apitegromab in children under the age of two living with SMA, are receiving apitegromab in conjunction with an approved SMN targeted treatment. These patients are reliant on the continued use and availability of such treatments. If access to an approved SMN targeted treatment such as nusinersen or risdiplam

Read in the 10-K

candidate may be delayed by many factors, including, for example, challenges in reaching consensus with regulatory agencies regarding the scope of the necessary preclinical study program and/or appropriate preclinical study designs.

Read in the 10-K
Show the other 15

For example, in September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility. This facility was issued a Form 483 by the FDA in July 2025 and the inspection classification of this facility is OAI. The observations were related to the facility and were not specific to apitegromab. In November 2025, we completed an in-person Type A meeting with the FDA that included participation of representatives from the third-party fill-finish facility. Also in November 2025, the third-party fill-finish facility received a warning letter from the FDA and continues to work with the FDA to resolve the outstanding issues cited in the warning letter.

Read in the 10-K

increased costs and could negatively affect our ability to develop and commercialize our product candidates in a timely manner or within budget.

Read in the 10-K

Failure to maintain compliance with cGMP can result in regulatory action against our third-party manufacturers, including FDA sanctions, which could disrupt our manufacturing and supply chain and lead to delays in our clinical development programs, regulatory submissions or approvals, or commercial supply, if approved. In addition, delays in securing or maintaining manufacturing capacity for drug substance, fill-finish, labeling and packaging, or failures by our contract manufacturers or suppliers to perform as required, could delay clinical trials, regulatory filings, or commercial launches, which could negatively affect our business.

Read in the 10-K

We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, ongoing military conflicts, new regulatory activities and economic policies, high inflation and interest rates and the imposition of tariffs, other trade barriers and retaliatory countermeasures, any of which could have a material adverse effect on our business, financial condition and results of operations.

U.S. and global markets have recently been experiencing volatility and disruption caused by economic uncertainty, including as a result of geopolitical instability, ongoing military conflicts, new regulatory activities and economic policies, and high inflation and interest rates. We are continuing to monitor global capital markets and assessing the potential impact of these factors on our business, including the impact on the supply chains we rely on for the manufacture of apitegromab, SRK-181, SRK-439, and any other current or future product candidates.

Although, to date, our business has not been materially impacted by the events described above, geopolitical tensions, or record inflation, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which such matters may impact our business. The extent and duration of such ongoing military conflicts, geopolitical tensions, record inflation and resulting market disruptions are impossible to predict but could be substantial. Any such disruptions may also magnify the impact of other risks we face.

Further, there have been, and may continue to be, significant changes to U.S. trade policies, sanctions, legislation, treaties and tariffs, including, but not limited to, trade policies and tariffs affecting products from outside of the U.S. The extent and duration of increased tariffs and the resulting impact on general economic conditions and on our business are uncertain and depend on various factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that may be granted, availability and cost of alternative sources of supply, and demand in affected markets. While many of our supply chain and manufacturing activities occur within the U.S., we rely on globally sourced raw materials, components, and consumables. As a result, changes in trade policies, including the imposition of tariffs, export restrictions, or other geopolitical restrictions could result in increased costs or cause delays in the procurement of necessary materials or services. Any such disruptions in the global supply chain caused by macroeconomic events and conditions could adversely affect the development, testing and clinical trials of apitegromab, SRK-181, SRK-439, and any future product candidates, or it may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.

Read in the 10-K

In addition, from time to time, there may be changes in our executive or senior management team that may be disruptive to our business. If our teams fail to execute our plans and strategies, including as a result of executive transitions, our business, financial condition, and results of operations could be adversely affected.

Read in the 10-K

In addition, federal and state efforts to impose new restrictions on manufacturer and third-party patient assistance programs could limit the availability or scope of these support services. Any such restrictions could reduce patient access to our products, which may materially and adversely affect our sales, business, and financial condition. Furthermore, patient support programs continue to face increased scrutiny from enforcement authorities. It is possible that regulators could determine that certain aspects of our programs do not comply with applicable healthcare fraud and abuse laws, including by viewing certain support services as improper inducements. Any such determination could have a significant adverse impact on our business, including the imposition of civil, criminal, or administrative penalties, and, in severe cases, exclusion from participation in federal and state healthcare programs.

On April 1, 2025, the Bureau of Industry and Security of the U.S. Department of Commerce initiated a Section 232 investigation on Pharmaceuticals and Pharmaceutical Ingredients, whose scope includes, but is not limited to, finished drug products, medical countermeasures, active pharmaceutical ingredients, starting materials, and derivative products of those items. This Section 232 investigation could result in substantial tariffs on these and related items, which could negatively impact our costs of production and operating margins. On October 31, 2025, CMS issued its final rule for the calendar‑year Physician Fee Schedule (“BFSF Certification Final Rule”), which requires manufacturers to obtain certifications from their third‑party vendors confirming that Bona Fide Service Fees (“BFSFs”) associated with Part B drug sales are not passed through, in whole or in part, to any client or customer, regardless of whether that entity takes title to the drug. Manufacturers must begin complying the BSFS Certification Final Rule beginning January 1, 2026. In addition to submitting these certifications to CMS, manufacturers must maintain detailed documentation supporting the reasonable assumptions used to calculate Average Sales Price (“ASP”), including the methodologies used to classify BFSFs for each contract. These new requirements may increase the risk that certain fees could be reclassified as price concessions, which would negatively affect a product’s ASP. Any such reclassification could reduce future reimbursement for our product(s) under Medicare Part B, which may materially and adversely impact our revenue.

Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and materially harm our business.

On May 12, 2025, President Trump issued an executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the U.S. and directing the Secretary of HHS to communicate MFN price targets to pharmaceutical manufacturers to align prices with those in comparably developed nations and, in the event significant progress towards MFN pricing is not delivered, to propose rulemaking to impose MFN pricing.

Since the May 12, 2025 order, the Trump administration has continued to exert pressure on drug manufacturers to implement MFN pricing, including by suggesting that the administration may impose significant tariffs on pharmaceuticals if such manufacturers do not reach agreements to implement MFN pricing. Further, in November 2025, the CMS introduced the GENEROUS Model, a voluntary Medicaid payment initiative under which participating drug manufacturers may voluntarily offer supplemental rebates to participating state Medicaid programs that are intended to provide such Medicaid programs with an MFN price for the manufacturers’ products. Additionally, in December 2025, CMS announced proposals for new mandatory demonstration payment models through two proposed rules under its CMMI authority, GLOBE for Medicare Part B and GUARD for Medicare Part D. If finalized, these models would impose additional mandatory rebates on manufacturers of certain Medicare Part B and Medicare Part D drugs, for select Medicare populations intended to represent 25% of Medicare patients, if the Medicare prices for such products exceed those paid in economically comparable countries. Both the GLOBE and GUARD models have proposed seven-year

testing periods, with the GLOBE model proposed to begin on October 1, 2026 and the GUARD model proposed to begin on January 1, 2027.

These reforms remain subject to change, potential legal challenges, or expansion through additional rulemaking or sub-regulatory guidance, creating uncertainty for our overall pricing strategy. It remains to be seen whether and how these drug pricing initiatives will apply to our product candidates, how they will affect the broader pharmaceutical industry, and whether similar reform measures may be adopted in the future.

Read in the 10-K

The GDPR also imposes strict rules on the transfers of personal data outside of the EEA or the UK to third countries, such as the US in certain circumstances, unless a derogation exists or a valid GDPR transfer mechanism (for example, the European Commission approved standard contractual clauses (“SCCs”) and the UK International Data Transfer Agreement/Addendum (“UK IDTA”)). Where relying on the SCCs or UK IDTA for data transfers, we may also be required to carry out transfer impact assessments to assess whether the recipient is subject to local laws which allow public authority access to personal data. The complexity and the additional contractual burden increases our overall risk exposure. There may be further divergence on international transfer safeguards in the future, including with regard to administrative burdens. Any inability to transfer personal data from the UK and EEA to the US (and other third countries) in compliance with data protection laws may adversely affect our operations and our business and financial position. The UK data protection regime is independent from but currently still aligned with the EEA’s data protection regime. However, going forward, there will be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the UK and EEA. Although the UK is regarded as a third country under the EU GDPR, the European Commission has issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. Similarly, the UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. However, the UK Data (Use and Access) Act 2025 now in force, may further differentiate the UK’s data protection regimes and could potentially impact the UK’s adequacy decision granted by the European Commission. The respective provisions and enforcement of the EU GDPR and UK GDPR may continue to diverge, creating additional regulatory challenges and uncertainty. This evolving regulatory landscape could increase legal risk, complexity and cost to our handling of personal data, and may require us to adapt our privacy and data security compliance programs to account for increasing legal and regulatory divergence between the UK and the EEA.

Read in the 10-K

significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for apitegromab.

Read in the 10-K

Even if apitegromab or any of our future product candidates receive marketing authorization in the EU or UK, we may be unable to successfully commercialize such products in those markets if we are unable to secure pricing and reimbursement on terms that are commercially acceptable. In most foreign countries, including several EU Member States, marketing authorization is only the first step toward patient access and the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely

from country to country. For example, each EU Member State conducts its own health technology assessment (“HTA”), pricing negotiations, and reimbursement decision-making, potentially resulting in delays of 12-24 months or more (on average) between EC approval and commercial availability. EU Member States can also restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Payers in many European countries impose increasingly stringent clinical, pharmacoeconomic, and budget-impact requirements that may differ significantly from those considered by regulatory authorities during the marketing authorization process. As a result, European authorities may conclude that the benefit–risk profile, real-world evidence, or incremental clinical value of apitegromab, when used as an adjunct to SMN-targeted therapies, does not justify the price we seek.

In December 2021, the Health Technology Assessment Regulation, Regulation (EU) 2021/2282, (“HTAR”) was adopted. The HTAR entered into force on January 11, 2022 and started to apply from January 12, 2025, with phased application depending on the category of health technology. Under the HTAR, EU Member States are required to use common HTA tools, methodologies, and procedures across the EU. Among others, the HTAR establishes an HTA coordination group, composed of national HTA bodies, which jointly conduct Joint Clinical Assessments (“JCAs”) of certain new medicines (including, in the initial phase, oncology medicines and advanced therapy medicinal products) and certain high-risk medical devices and provides for a single EU-level dossier submission for the purposes of JCAs. However, the HTAR focuses on the clinical aspects of HTA, i.e. the relative clinical effectiveness and relative clinical safety of a new health technology compared with relevant existing health technologies, and, as such, individual EU Member States remain responsible for determining the overall value of a new health technology within their healthcare systems, as well as making pricing and reimbursement decisions.

Read in the 10-K

There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for apitegromab. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower and, in certain countries, below levels required for commercial viability. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. Moreover, any delays or negative outcomes in pricing or reimbursement negotiations in major markets such as Germany, France, Italy, Spain, or the UK could adversely influence decisions in other EU Member States due to cross-border reference pricing, or coordinated negotiation mechanisms that are increasingly being adopted across the EU. A low price, stringent reimbursement limitation, or reimbursement denial in one influential country may therefore have a cascading effect across multiple markets. In addition, if negotiated EU list prices become public, an unfavorable price published in one EU Member State could place pressure on pricing negotiations in other jurisdictions.

If pricing is set at unsatisfactory levels or if reimbursement of apitegromab is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of apitegromab in those countries would be negatively affected. If we are unable to secure satisfactory pricing and reimbursement in the EU, or if the reimbursement landscape evolves in ways that impose additional uncertainty, delay, or financial burden, we may be unable to realize the full commercial potential of apitegromab or any future product candidate in these markets. Any of these events could materially adversely affect our business, prospects, financial condition and results of operations.

Read in the 10-K

develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected.

Read in the 10-K

could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.

Read in the 10-K

We no longer qualify as a smaller reporting company as of January 1, 2026, which will increase our costs and demands on management.

Based on the market value of our common stock held by our non-affiliates as of June 30, 2025, we are no longer a smaller reporting company as of January 1, 2026, and thus will be subject to additional disclosure and compliance requirements beginning with our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Due to this upcoming transition, we expect to devote significant time and effort to implement and comply with the additional standards, rules and regulations that will apply to us upon losing our smaller reporting company status. Compliance with the additional requirements will also increase our legal, accounting and financial compliance costs.

As a smaller reporting company, we availed ourselves of the exemption from the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002. Upon losing our smaller reporting company status beginning with our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, we will no longer be able to rely on the scaled disclosure requirements and other accommodations available to smaller reporting companies. This may require us to provide additional disclosures in our periodic reports, including more detailed executive compensation disclosures and additional financial statement information. The transition from smaller reporting company status will require significant resources, including additional personnel, enhanced systems and processes, and increased professional fees for accounting, legal, and compliance services. We will need to implement more comprehensive internal controls and procedures to meet the heightened requirements applicable to larger public companies. Due to the complexity and logistical difficulty of implementing the standards, rules and regulations that apply to non-smaller reporting companies, there is an increased risk that we may be found to be in non-compliance with such standards, rules and regulations or to have significant deficiencies or material weaknesses in our internal controls over financial reporting. Any failure to maintain effective disclosure controls and internal control over financial reporting could materially and adversely affect our business, results of operations and financial condition, and could cause a decline in the trading price of our common stock.

Read in the 10-K

investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.

Read in the 10-K

inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 10, 2026 that were not in the one before

New in the latest 10-Q

66 paragraphs in the 10-Q filed Nov 10, 2026 with nothing like them in the 10-Q filed Aug 6, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

10-Q

• the ability to maintain regulatory approval of ISEMBYLD™ (apitegromab-mstn) from the U.S. Food and Drug Administration (“FDA”) and successfully complete the post-marketing requirements from the FDA;

Read in the 10-Q

Financial statements and notes

Inventory is comprised of raw materials, work-in-process and finished goods, and includes costs related to third-party contract manufacturing, packaging, freight-in and overhead. Inventory is stated at the lower of cost or net realizable value with cost based on the first-in-first-out method. Materials that may be used for either research and development or commercial purposes where the intended use is not yet known are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is used or otherwise allocated for research and development, it is expensed as research and development in the period that determination is made.

Read in the 10-Q

Prior to regulatory approval of its product candidates, the Company expenses costs associated with the manufacturing of its product candidates to research and development expense unless the Company is reasonably certain such costs have future commercial use and net realizable value. When the Company believes regulatory approval and subsequent commercialization of its product candidates is probable, and the Company also expects future economic benefit from the sales of the product candidates to be realized, the Company will then capitalize the costs of production as inventory.

Read in the 10-Q

The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded within cost of product revenue. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required, which would be recorded as a cost of product revenue in the statements of operations. There were no expenses recorded for excess inventory or other impairments during the three and nine months ended September 30, 2026.

Read in the 10-Q

The Company recognizes net product revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, which outlines a five-step process for recognizing revenue from contracts with customers: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the separate performance obligations in the contract, and (v) recognize revenue associated with the performance obligations as they are satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company sells ISEMBYLD™ (apitegromab-mstn) (the “Product”) in the U.S. to a specialty distributor, which resells the Product to qualified healthcare providers and to specialty pharmacies, which dispense the Product for administration to patients. The Company has determined that the delivery of the Product to a Customer constitutes a single performance obligation that is satisfied at a point in time, when control of the Product transfers upon delivery to the Customer’s designated facility. Net product revenue is recognized at that time, measured at the transaction price.

Read in the 10-Q
Show the other 61

The trade payment terms with the Company’s customers do not exceed one year and therefore the Company has elected to apply the practical expedient and no amount of consideration has been allocated as a financing component.

Read in the 10-Q

Net product revenue is recorded at the transaction price, which reflects adjustments for chargebacks, government and commercial rebates, product and prompt pay discounts, and distributor and specialty pharmacy service fees, co-pay assistance and product returns (collectively, “gross-to-net adjustments”). These adjustments represent variable consideration under ASC 606 and are estimated using the expected value method or most likely amount method and are recorded when revenue is recognized on the sale of the Product. Gross-to-net adjustments are presented as reductions of accounts receivable when settlement is expected to occur through a reduction of the amount paid by the Customer, and as accrued liabilities when settlement is expected to occur through a payment from the Company. The gross-to-net adjustments are estimates based upon information received from external sources, such as written or oral information obtained from customers with respect to their period-end inventory levels and sales to end-users during the period, in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual results in the future may vary from the Company’s original estimates. The Company will adjust these estimates in the period such variances become known, which would affect net product revenue and earnings.

Read in the 10-Q

Chargebacks - Chargebacks represent the estimated obligations to Customers resulting from the difference in contractual and statutory commitments to make the Product available to certain downstream purchasers, including 340B covered entities and federal agencies, at prices lower than the list price charged to Customers who directly purchase the Product from the Company. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable, and consist of amounts that Customers have claimed but for which the Company has not yet issued a credit, together with the credits the Company expects to issue for Product remaining in the distribution channel at the end of each reporting period.

Read in the 10-Q

Government and Commercial Rebates - The Company is subject to rebate obligations under government programs, including the Medicaid Drug Rebate Program and the Medicare Part D Manufacturer Discount Program, and expects to enter into rebate arrangements with commercial payers and pharmacy benefit managers in exchange for coverage of, and formulary position for, the Product. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. The Company’s liability for these rebates consists of invoices received for claims that have not been paid or for which an invoice has not yet been received, estimates of claims for the current period, and estimated future claims for Product that has been recognized as revenue, but remains in the distribution channel.

Read in the 10-Q

Discounts - Certain Customer agreements provide for a contractual discount from the Company’s wholesale acquisition cost that is reflected directly on the Customer’s invoice; product revenue and accounts receivable are recorded as the net invoiced amount. The Company estimates prompt pay discounts based on contractual terms and expectations regarding future customer payment patterns. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable.

Read in the 10-Q

Distributor and Specialty Pharmacy Service Fees - The Company pays fees to its specialty distributor and specialty pharmacy customers for distribution and other services, including a specialty distributor fee based on a contractually determined fixed percentage of sales and specialty pharmacy fees for program and account management, inventory management, enhanced nursing services, data reporting and shipping. To the extent that the Company has determined that these services are not distinct from the Customer’s purchase of the Product, the adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. Where the Company has determined these services are distinct and at fair value, the fees for such services are recorded as operating expenses as the services are provided.

Read in the 10-Q

Copay Assistance - The Company offers a co-pay assistance program, which is intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payers. Patients whose Product is reimbursed by a federal or state health care program are not eligible for the program. The Company estimates co-pay assistance using program participation and redemption data provided by the third-party administrator of the program, including amounts expected to be redeemed on Product remaining in the distribution channel, and records the estimate as a reduction of product revenue.

Read in the 10-Q

Product Returns - The Company’s contracts with its Customers generally provide for returns only if the Product is damaged or defective upon delivery, if there is a shipment error, or if the product is within an eligible expiry window. The Company estimates product return reserves using contractual terms, Product shelf life, contracted days-on-hand limits, available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and a refund liability, which is included in accrued expenses and other current liabilities in the Company’s financial statements.

Read in the 10-Q

7. Product Revenues, Net, Accounts Receivable, Net and Reserves for Product Revenues On September 11, 2026, the U.S. Food and Drug Administration (“FDA”) approved ISEMBYLD for the treatment of SMA in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (“SMN2”)-targeted treatment. During the three and nine months ended September 30, 2026 we recorded net product revenue of $0.6 million from sales of ISEMBYLD in the U.S. The following table summarizes the Company’s product revenues, by customer, for those customers that exceeded 10% of gross revenue for the periods indicated: Three and Nine Months Ended September 30, 2026 2025 Customer 1 50% % Customer 2 25% % Customer 3 16% % ──────────────────────────────────────────────────────────────────────────────── As of September 30, 2026, the Company's accounts receivable, net were $0.7 million and related to product sales in the U.S., net of discounts and allowances. All customers in the U.S. have standard payment terms that generally require payment within 65 to 90 days. Three customers accounted for 50%, 25% and 16% of the total accounts receivable balance as of September 30, 2026. The following tables summarize an analysis of the change in reserves for discounts and allowances for each of the periods indicated: Chargebacks Rebates Co-Pay Other Accruals Total (in thousands) Balance, as of December 31, 2025 $ - $ - $ - $ - $ - Provision 60 46 37 98 241 Adjustments relating to prior periods - - - - - Payments/credits - - - - - Balance, as of September 30, 2026 $ 60 $ 46 $ 37 $ 98 $ 241

Read in the 10-Q

8. Inventory The following table summarizes the components of the Company’s inventory for each of the periods indicated: As of September 30, December 31, 2026 2025 Raw Materials $ - $ Work In Process 312 Finished Goods 461 Total inventory $ 773 $ Prior to regulatory approval of ISEMBYLD, the Company expensed costs associated with the manufacturing of apitegromab to research and development expense. There were no inventory losses for write-downs of excess and obsolete inventory for the three and nine months ended September 30, 2026.

Read in the 10-Q

Consists of other segment expenses related to supplies, corporate and facilities expenses.

Read in the 10-Q

16. Subsequent Events On November 9, 2026, the Company entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”) with BioNTech US Inc. (the “Buyer”), pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) to Buyer for $205.0 million in cash upon the closing of the sale. The Company received the PRV in connection with the FDA approval of ISEMBYLD in September 2026. The transaction remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Read in the 10-Q

is currently underway. The company expects to have topline data by year end 2026 and plans to share data from this study in the first quarter of 2027.

Read in the 10-Q

In September 2026, we commenced commercialization of ISEMBYLD in the U.S. following FDA approval. As a result, we expect to generate product revenue from sales of ISEMBYLD while continuing to incur substantial expenses associated with commercialization activities, including sales, marketing, medical affairs, manufacturing, distribution and post-approval development activities. Although we have begun generating product revenue, we expect to continue to incur significant operating losses for the foreseeable future as we commercialize ISEMBYLD and advance our development pipeline.

Read in the 10-Q

On September 11, 2026, the FDA approved ISEMBYLD for the treatment of SMA in adults and children two years of age and older who are currently receiving SMN2-targeted treatment. We began commercial shipments of ISEMBYLD in the U.S. during the third quarter of 2026 and therefore began recognizing product revenue during the quarter. We sell ISEMBYLD in the U.S. to a specialty distributor, which resells the ISEMBYLD to qualified health care providers, and to specialty pharmacies, which dispenses ISEMBYLD for administration to patients. We record product revenue net of estimated variable consideration, including chargebacks, government and commercial rebates, discounts, distributor and specialty pharmacy service fees, copay assistance and estimated product returns. Product revenue during the launch period reflects sales to our customers, including inventory build within the channel, and may not directly correspond to patient starts, infusions or underlying patient demand during the period.

Read in the 10-Q

Cost of product revenue includes the cost of producing and distributing inventories that are related to product revenue and may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, or other reasons. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of ISEMBYLD recorded during the three months ended September 30, 2026 were expensed prior to FDA approval of ISEMBYLD. This inventory carries a lower cost basis, resulting in lower cost of product revenue and higher gross margin during the initial commercialization period. We had expensed $25.6 million for this inventory prior to receiving approval on September 11, 2026.

Read in the 10-Q

Prior to the regulatory approval of our drug candidates, we incurred expenses for the manufacture of drug product supplies to support clinical development that could potentially be available to support the commercial launch of those drugs. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses.

Read in the 10-Q

For the three months ended September 30, 2026, we recorded cost of product revenue of $8,000 related to sales of ISEMBYLD in the United States. Prior to the FDA approval of ISEMBYLD, product costs were expensed as research and development expense.

Read in the 10-Q

$0.3 million increase in costs associated with other early development candidates and unallocated costs;

Read in the 10-Q

In September 2026, the U.S. Food and Drug Administration (“FDA”) approved ISEMBYLD for the treatment of SMA in adults and

Read in the 10-Q

children two years of age and older who are currently receiving a survival motor neuron 2 (“SMN2”)-targeted treatment. For the nine months ended September 30, 2026, we recorded net product revenue of $0.6 million from sales of ISEMBYLD in the U.S. There was no net product revenue for the nine months ended September 30, 2025.

Read in the 10-Q

For the nine months ended September 30, 2026, we recorded cost of product revenue of $8,000 related to sales of ISEMBYLD in the U.S. Prior to the FDA approval of ISEMBYLD, product costs were expensed as research and development expense.

Read in the 10-Q

In connection with the approval of ISEMBYLD, we were issued a Rare Pediatric Disease priority review voucher (“PRV”) by the FDA. The PRV can be used to obtain priority review of a subsequent marketing application or sold or transferred to another sponsor. In November 2026, we entered into an asset purchase agreement with BioNTech US Inc., pursuant to which we agreed to sell our PRV for $205.0 million in cash upon the closing of the sale. The transaction remains subject to customary closing conditions. See Note 16, “Subsequent Events,” to our condensed consolidated financial statements.

Read in the 10-Q

• the costs associated with maintaining regulatory approvals for ISEMBYLD, obtaining approvals in additional jurisdictions and pursuing approvals for additional indications;

Read in the 10-Q

Risk Factors

• Our near-term prospects are wholly dependent on the successful commercialization of ISEMBYLD. We have limited experience commercializing an approved product, and if we are unable to successfully commercialize ISEMBYLD in the U.S. for its approved indication, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.

Read in the 10-Q

Our near-term prospects are wholly dependent on the successful commercialization of ISEMBYLD. We have limited experience commercializing an approved product, and if we are unable to successfully commercialize ISEMBYLD in the U.S. for its approved indication, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.

Read in the 10-Q

On September 11, 2026, the FDA approved ISEMBYLD for the treatment of SMA in adults and children two years of age and older who are currently receiving SMN2-targeted treatment. We have recently launched ISEMBYLD in the U.S. for that indication.

Read in the 10-Q

ISEMBYLD is our only product approved for marketing by the FDA, and our ability to generate revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize ISEMBYLD in the U.S. for its approved indication. We may not be able to successfully commercialize ISEMBYLD for a number of reasons, including:

Read in the 10-Q

• we may not be able to establish or demonstrate in the medical community the safety and efficacy of ISEMBYLD;

Read in the 10-Q

• physicians may be reluctant to prescribe ISEMBYLD until longer-term efficacy and safety data exists;

Read in the 10-Q

• we have limited experience in marketing, selling and distributing ISEMBYLD or any other product;

Read in the 10-Q

• we are dependent on the reimbursement and coverage policies of government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators and may not be able to obtain adequate reimbursement and coverage for ISEMBYLD;

Read in the 10-Q

• we may be unable to secure or maintain favorable coverage, reimbursement and formulary access for ISEMBYLD on acceptable terms or within expected timeframes;

Read in the 10-Q

• sales may be affected by the relative price of ISEMBYLD as compared to alternative treatment options;

Read in the 10-Q

• sales volumes will depend on the incidence and prevalence of patients in ISEMBYLD’s approved indication, and our market and sales estimates may be incorrect;

Read in the 10-Q

• physicians, patients and payors may have concerns regarding the safety profile of ISEMBYLD, which could limit prescribing, slow patient adoption, result in additional monitoring requirements or adversely affect reimbursement, market access and the commercial success of ISEMBYLD;

Read in the 10-Q

• future competitive or other market factors may adversely affect the commercial potential of ISEMBYLD;

Read in the 10-Q

• we may not be able to obtain and maintain regulatory approvals for ISEMBYLD in any other jurisdictions or for any other apitegromab indications;

Read in the 10-Q

• changes could be required to the label for ISEMBYLD that restrict how we market and sell ISEMBYLD, including as a result of adverse events observed following commercialization or in ongoing and future studies of ISEMBYLD;

Read in the 10-Q

• we may encounter manufacturing challenges that may impact product supply or may need to conduct product recalls;

Read in the 10-Q

• we might not be able to maintain compliance with the legal and regulatory requirements for the manufacturing, marketing, promotion, sale, distribution and commercialization of ISEMBYLD and may face enforcement actions;

Read in the 10-Q

• we may not be able to maintain adequate commercial supplies of ISEMBYLD, or there may not be adequate supplies of apitegromab to meet demand at an acceptable cost or at all; and

Read in the 10-Q

• we may need additional financial or other resources to successfully commercialize ISEMBYLD.

Read in the 10-Q

Moreover, successful commercialization of ISEMBYLD may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all. If we are unable to successfully commercialize ISEMBYLD in the U.S. for its approved indication, our ability to generate meaningful revenue from product sales and achieve profitability will be materially and adversely affected, which in turn could have a material adverse effect on our business and business prospects.

Read in the 10-Q

The third-party fill-finish facility included in our original MAA received an OAI inspection classification from the FDA following inspections in 2025 and again in 2026. As a result, and following discussions with the EMA, we withdrew our original MAA and resubmitted the application in October 2026 to incorporate an alternate fill-finish facility. The EMA will require time to review the resubmitted MAA and there is no guarantee that the EMA will give a positive opinion on the grant of a marketing authorisation for apitegromab on the basis of the resubmitted MAA. In addition, in November 2026 we submitted our JNDA for apitegromab to the PMDA, and there can be no assurance that the PMDA will complete its review within our anticipated timeframe or approve apitegromab for the indication or patient population sought, if at all. The PMDA may request additional data or analyses or impose other requirements in connection with its review of our application, which could delay or prevent regulatory approval of apitegromab in Japan.

Read in the 10-Q

• the indications for which other apitegromab indications or product candidates are approved;

Read in the 10-Q

Market acceptance of our product candidates is heavily dependent on patients’ and physicians’ perceptions that our products and product candidates are safe and effective treatments for their targeted indications and willingness to use screening and/or diagnostic tests to identify at-risk target populations for our products and product candidates, if approved. The perceptions of any product are also influenced by perceptions of competitors’ products that are in the same class or that have a similar mechanism of action. Because we expect sales of our ISEMBYLD to generate substantially all our revenues in the foreseeable future, the failure of ISEMBYLD to find market acceptance would harm our business.

Read in the 10-Q

The ability of the FDA and foreign regulatory authorities to review and or approve new products can be affected by a variety of factors, including government budget and funding levels, staffing levels, and statutory, regulatory, and policy changes, the FDA’s and

Read in the 10-Q

Commercial use of ISEMBYLD also requires patients to receive an SMN2-targeted treatment. Accordingly, limitations on the availability of, or our patients’ access to, these third-party therapies, including due to supply disruptions, safety concerns, regulatory restrictions or inadequate insurance coverage or reimbursement, could limit patients’ ability to initiate or continue treatment with ISEMBYLD. We do not control the manufacture, supply, pricing or reimbursement of these therapies. Any resulting reduction in the number of patients able to receive ISEMBYLD could adversely affect its commercial adoption and sales. These clinical and commercial risks could harm our business, financial condition and results of operations.

Read in the 10-Q

There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical development even after achieving promising

Read in the 10-Q

We also rely on third-party commercial distributors to distribute ISEMBYLD and may rely on these or other distributors for any products approved in the future. Our ability to successfully commercialize our product depend in part on these distributors’ ability to fulfill orders accurately and on a timely basis, maintain appropriate inventory levels, comply with applicable storage, handling and distribution requirements, and provide timely and accurate inventory and sales information. We have limited control over these third parties, and their failure to perform their contractual obligations or comply with applicable legal and regulatory requirements, or disruptions to their operations, could interrupt product distribution, delay patient access, result in product loss or additional costs, and adversely affect our sales and revenue. If any of these relationships terminate or a distributor is unable or unwilling to continue distributing our product, we may not be able to establish alternative arrangements in a timely manner or on commercially reasonable terms, which could materially adversely affect our business, financial condition and results of operations.

Read in the 10-Q

reputational harm, diminished profits and future earnings and the curtailment of our operations, any of which could adversely affect our ability to operate our business, financial condition and results of operations.

Read in the 10-Q

As part of our commercialization strategy, particularly in smaller jurisdictions outside the U.S., we may engage third-party distributors, commercialization partners, service providers and other agents to market, sell, distribute or otherwise support access to our products. Although we intend to conduct appropriate diligence and maintain contractual and compliance controls over such third parties, we may not be able to effectively monitor or control all of their activities. If any such third party engages in conduct that violates applicable healthcare, anti-corruption, anti-kickback, false claims, privacy, trade, sanctions, competition, pricing and reimbursement or other laws and regulations, or otherwise fails to comply with applicable regulatory requirements, we could be subject to investigations, enforcement actions, fines, penalties, reputational harm, contractual liability, restrictions on commercialization activities or other adverse consequences, even if we were not aware of, did not authorize or did not directly participate in such conduct.

Read in the 10-Q

GUARD remains a proposed regulation that has not been finalized and, as proposed, would similarly mandate manufacturer rebates for qualifying sole source drugs where the Medicare net price exceeds an MFN benchmark derived from international reference pricing methodologies, with its performance period proposed to begin in 2027. The GLOBE model and the proposed GUARD model will likely be subject to legal challenges that could delay implementation or modify their impact on manufacturer pricing and revenue. Additionally, in November 2025, CMS introduced the GENErating cost Reductions for U.S. Medicaid (“GENEROUS”) Model, a voluntary MFN framework for manufacturers participating in the Medicaid Drug Rebate Program. Although it is voluntary, the GENEROUS Model could also impact the drug pricing landscape for manufacturers.

Read in the 10-Q

pharmaceutical manufacturer to incur significant legal expenses and divert management’s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.

Read in the 10-Q

If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

Read in the 10-Q

We participate in the Medicaid Drug Rebate Program, the 340B program, the U.S. Department of Veterans Affairs, Federal Supply Schedule (“FSS”) pricing program, and the Tricare Retail Pharmacy program, which require us to disclose average manufacturer pricing, and, in the future may require us to report the average sales price for certain of our drugs to the Medicare program. Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies and the courts. Furthermore, regulatory and legislative changes, and judicial rulings relating to these programs and policies (including coverage expansion), have increased and will continue to increase our costs and the complexity of compliance, have been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS or another agency challenges the approach we take in our implementation. For example, in the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data, we are generally obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements increase our costs and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program and give rise to an obligation to refund entities participating in the 340B program for overcharges during past quarters impacted by a price recalculation.

Read in the 10-Q

Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. Additionally, our agreement to participate in the 340B program or our Medicaid drug rebate agreement could be terminated, in which case federal payments may not be available under Medicaid or Medicare Part D for our covered outpatient drugs. Additionally, if we overcharge the government in connection with our arrangements with FSS or Tricare Retail Pharmacy, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act (“FCA”) and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

Read in the 10-Q

Further, legislation may be introduced that, if passed, would, among other things, further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting, and any additional future changes to the definition of average manufacturer price or the Medicaid rebate amount could affect our 340B ceiling price calculations and negatively impact our results of operations. Additionally, certain pharmaceutical manufacturers are involved in ongoing litigation regarding contract pharmacy arrangements under the 340B program. The outcome of those judicial proceedings and the potential impact on the way in which manufacturers extend discounts to covered entities through contract pharmacies remain uncertain.

Read in the 10-Q

• Subject to current transitional provisions, which are currently scheduled to expire in May 2030, published European patent applications and European patents can be opted out of the jurisdiction of the UPC. The timing and form of an opt-out can be important to its effectiveness and the opt-out status may affect the litigation strategy options available, including choice of forum.

Read in the 10-Q

cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our shareholders’ tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 10, 2026 against Item 1A of the 10-K filed Mar 3, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

Added10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
• Our near-term prospects are wholly dependent on the successful commercialization of ISEMBYLD. We have limited experience commercializing an approved product, and if we are unable to successfully commercialize ISEMBYLD in the U.S. for its approved indication, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.

Read it in the 10-Q at sec.gov

Added10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
Our near-term prospects are wholly dependent on the successful commercialization of ISEMBYLD. We have limited experience commercializing an approved product, and if we are unable to successfully commercialize ISEMBYLD in the U.S. for its approved indication, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.

Read it in the 10-Q at sec.gov

Added10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
On September 11, 2026, the FDA approved ISEMBYLD for the treatment of SMA in adults and children two years of age and older who are currently receiving SMN2-targeted treatment. We have recently launched ISEMBYLD in the U.S. for that indication.

Read it in the 10-Q at sec.gov

Added10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
ISEMBYLD is our only product approved for marketing by the FDA, and our ability to generate revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize ISEMBYLD in the U.S. for its approved indication. We may not be able to successfully commercialize ISEMBYLD for a number of reasons, including:

Read it in the 10-Q at sec.gov

Show the other 26
Added10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
• we are dependent on the reimbursement and coverage policies of government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators and may not be able to obtain adequate reimbursement and coverage for ISEMBYLD;

Read it in the 10-Q at sec.gov

Added10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
• we may be unable to secure or maintain favorable coverage, reimbursement and formulary access for ISEMBYLD on acceptable terms or within expected timeframes;

Read it in the 10-Q at sec.gov

Added10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
• sales volumes will depend on the incidence and prevalence of patients in ISEMBYLD’s approved indication, and our market and sales estimates may be incorrect;

Read it in the 10-Q at sec.gov

Added10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
• physicians, patients and payors may have concerns regarding the safety profile of ISEMBYLD, which could limit prescribing, slow patient adoption, result in additional monitoring requirements or adversely affect reimbursement, market access and the commercial success of ISEMBYLD;

Read it in the 10-Q at sec.gov

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
Even if Although we have recently received approval from the FDA, FDA for ISEMBYLD, for the treatment of SMA in adults and children two years of age and older who are currently receiving SMN2-targeted treatment, the EMA, PMDA or other regulatory authorities were to grant approval for apitegromab in SMA, one or more of these regulatory authorities may determine that the approval should be further limited to a subset b of SMA patients, which could restrict the commercial potential of apitegromab ISEMBYLD in SMA.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
On February 27, 2026, we terminated our previous Amended and Restated the Oxford Loan and Security Agreement, dated as of February 10, 2025 with Oxford Finance LLC (“Oxford” and such agreement, as amended, the “Existing Loan Agreement”) Agreement and entered into a Financing the 2026 Loan Agreement (the “Financing Agreement”) with certain funds managed by Blue Owl Capital Corporation (“Blue Owl”). Owl.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
We expect to continue to invest significant financial and management resources over time to establish in our compliance, medical affairs and commercial organizations for to support the marketing, sales and distribution ongoing commercialization of apitegromab ISEMBYLD in the United States U.S. and potential launches in Europe, if approved in each jurisdiction, Japan and other capabilities and infrastructure to support commercial operations. jurisdictions, if approved.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
Our increased reliance on personnel working from home may increase our cyber security risk, create data accessibility concerns, and make us more susceptible to workforce and communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other agencies and contractors.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
If apitegromab is approved but ISEMBYLD, or other product candidates if approved, fails to achieve market acceptance among hospitals, physicians, patients or health care payors, we will not be able to generate significant revenues and we may not become profitable, which would have a material adverse effect on our business, prospects, financial condition and results of operations.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
If any actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment of our operations, any of which could adversely affect our ability to operate our business, financial condition and results of operations.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
We face an inherent risk of product liability as a result of testing apitegromab, SRK-181, SRK-439 and any the use of our future product commercially, and the clinical testing of our product candidates in clinical trials and will face an even greater risk if as we commercialize any products, if approved. additional products in the future.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA, MHRA MHRA, PMDA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA, EMA EMA, PMDA and other similar foreign regulatory bodies; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws; engage in appropriate sales, marketing, pricing, reimbursement, patient support, product distribution, import/export, anti-corruption or other commercial activities in connection with ISEMBYLD or apitegromab or report financial information or data accurately or to disclose unauthorized activities to us.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
Additionally, in In December 2025, the CMS announced proposals for new mandatory demonstration payment models through two proposed rules under its CMMI authority, GLOBE CMS Innovation Center (“CMMI”) authority: the Global Benchmark for Efficient Drug Pricing Model (“GLOBE”) for Medicare Part B and GUARD for Medicare Part D. the Guarding U.S.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
Even if we obtain coverage for apitegromab, the resulting The reimbursement payment rates might established by third-party payors may not be adequate for us to achieve or sustain profitability or and may require co-payments that patients find unacceptably high. be reduced over time.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
For example, the EU’s Artificial Intelligence Act (“AI Act”), the world’s first comprehensive AI law, entered into force on August 1, 2024, and most provisions of which will become effective on August 2, 2026. 2026 although the application of certain requirements for high-risk AI systems has been deferred until December 2, 2027 (or for certain product-embedded AI systems, August 2, 2028).

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
See the sections in this our Annual Report on Form 10-K for the year ended December 31, 2025 entitled “Business– “Business - Government Regulation – - Coverage and Reimbursement” and “Business–Government Regulation–Current “Business - Government Regulation - Current and Future Healthcare Reform Legislation.” Legislation. ”

Read it in the 10-Q at sec.govThe 10-K sentence

Quiet changes10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
Competing therapies may exist or could emerge that adversely affect the amount of revenue we are able to generate from the sale of apitegromab, if approved, ISEMBYLD or any of our future product candidates, if successfully developed and approved.

Read it in the 10-Q at sec.govThe 10-K sentence

Quiet changes10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
Upon losing our smaller reporting company status beginning with our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, we will are no longer be able to rely on the scaled disclosure requirements and other accommodations available to smaller reporting companies.

Read it in the 10-Q at sec.govThe 10-K sentence

Quiet changes10-Q Nov 10, 2026 vs 10-K Mar 3, 2026
The transition from smaller reporting company status will require requires significant resources, including additional personnel, enhanced systems and processes, and increased professional fees for accounting, legal, and compliance services.

Read it in the 10-Q at sec.govThe 10-K sentence

The first 31 of 155 are shown (at most 12 of each type).

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Mar 3, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 27, 2025

fill-finish facility ×9third-party fill-finish ×8health technology ×6loan agreement ×6blue owl ×6warning letter ×5medicare part ×5apitegromab bla ×4supply chain ×4mfn pricing ×4financing agreement ×4sma patients ×3progress toward ×3toward potential ×3reimbursement decisions ×3technology assessment ×3
Where each one is used
  • fill-finish facility: In September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility. This facility was issued a Form 483 by the FDA in July 2025 and the inspection classification of this facility is OAI. The observations were related to the facility and...
  • third-party fill-finish: In September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility. This facility was issued a Form 483 by the FDA in July 2025 and the inspection classification of this facility is OAI. The observations were related to the facility and...
  • health technology: Unfavorable pricing and reimbursement decisions in the EU could significantly delay or limit patient access to apitegromab, if approved, and materially reduce our anticipated revenues. Even if we obtain marketing authorization, the EU health technology assessment bodies and national payors may impose price...
  • loan agreement: The terms of our loan agreements place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
  • blue owl: On February 27, 2026, we terminated our previous Amended and Restated Loan and Security Agreement, dated as of February 10, 2025 with Oxford Finance LLC (“Oxford” and such agreement, as amended, the “Existing Loan Agreement”) and entered into a Financing Agreement (the “Financing Agreement”) with certain funds...
  • warning letter: In September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility. This facility was issued a Form 483 by the FDA in July 2025 and the inspection classification of this facility is OAI. The observations were related to the facility and...
  • medicare part: On April 1, 2025, the Bureau of Industry and Security of the U.S. Department of Commerce initiated a Section 232 investigation on Pharmaceuticals and Pharmaceutical Ingredients, whose scope includes, but is not limited to, finished drug products, medical countermeasures, active pharmaceutical ingredients, starting...
  • apitegromab bla: The regulatory approval process for apitegromab in the U.S., EU and other jurisdictions will be lengthy, time-consuming and inherently unpredictable and we may fail to receive or be delayed in receiving regulatory approval of apitegromab, or we may receive regulatory approval for only a subset of SMA patients. The...

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

29 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
The EU GDPR ceased to apply in the UK after the UK’s exit from the EU on January 31, 2020, but the UK incorporated the EU GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law (“ the UK GDPR”). The UK GDPR and the UK Data Protection Act 2018 set out the UK’s data protection regime, which is independent from but currently still aligned to the EU’s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to £17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third...
In the 10-K filed Feb 27, 2025
Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions at which such trials are being conducted, or the FDA, the competent authorities and/or ethics committees of the EU Member States or other regulatory authorities, or recommended for suspension or termination by the DSMB for such trial, due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, competent authorities of the EU Member States...
In the 10-K filed Feb 27, 2025
While we are no longer an “emerging growth company”, we are a “smaller reporting company” as defined in the Exchange Act, and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies, including reduced disclosure obligations regarding executive compensation if we are eligible to do so. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to audit our internal control over financial reporting for so long as we report less than $100 million in...
In the 10-K filed Feb 27, 2025
In addition, as appropriate, we may seek accelerated assessment of a marketing authorization application by the EMA for certain of our product candidates. The EMA may accept an application for accelerated assessment if the applicant can show that its product is of major interest for public health, particularly from the perspective of therapeutic innovation. Accelerated assessment reduces the timeframe for the EMA to review a marketing authorization application under the centralized procedure from 210 days (excluding “clock stops”, when applicants are required to provide additional...
In the 10-K filed Feb 27, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRRK/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.